title: Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
abstract: Genomic heterogeneity is characteristic of glioblastoma (GBM). In many GBMs, the EGF receptor gene (EGFR) is amplified and may be truncated to generate a constitutively active form of the receptor called EGFRvIII. EGFR gene amplification and EGFRvIII are associated with GBM progression, even when only a small fraction of the tumor cells express EGFRvIII. In this study, we show that EGFRvIII-positive GBM cells express significantly increased levels of cellular urokinase receptor (uPAR) and release increased amounts of soluble uPAR (suPAR). When mice were xenografted with human EGFRvIII-expressing GBM cells, tumor-derived suPAR was detected in the plasma, and the level was significantly increased compared with that detected in plasma samples from control mice xenografted with EGFRvIII-negative GBM cells. suPAR also was increased in plasma from patients with EGFRvIII-positive GBMs. Purified suPAR was biologically active when added to cultures of EGFRvIII-negative GBM cells, activating cell signaling and promoting cell migration and invasion. suPAR did not significantly stimulate cell signaling or migration of EGFRvIII-positive cells, probably because cell signaling was already substantially activated in these cells. The activities of suPAR were replicated by conditioned medium (CM) from EGFRvIII-positive GBM cells. When the CM was preincubated with uPAR-neutralizing antibody or when uPAR gene expression was silenced in cells used to prepare CM, the activity of the CM was significantly attenuated. These results suggest that suPAR may function as an important paracrine signaling factor in EGFRvIII-positive GBMs, inducing an aggressive phenotype in tumor cells that are EGFRvIII-negative.
authors.affiliation: From the Departments of Pathology and.
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Gilder
authors.affiliation: From the Departments of Pathology and.
authors.forename: Karra A
authors.initials: KA
authors.lastname: Jones
authors.affiliation: From the Departments of Pathology and.
authors.forename: Jingjing
authors.initials: J
authors.lastname: Hu
authors.affiliation: From the Departments of Pathology and.
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.affiliation: Surgery, Division of Neurosurgery, University of California at San Diego, La Jolla, California 92093.
authors.forename: Clark C
authors.initials: CC
authors.lastname: Chen
authors.affiliation: Surgery, Division of Neurosurgery, University of California at San Diego, La Jolla, California 92093.
authors.forename: Bob S
authors.initials: BS
authors.lastname: Carter
authors.affiliation: From the Departments of Pathology and sgonias@ucsd.edu.
authors.forename: Steven L
authors.initials: SL
authors.lastname: Gonias
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000378:metabolism*; D005909:Glioblastoma / Q000378:metabolism* / Q000473:pathology; D064593:Heterografts; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D016133:Polymerase Chain Reaction; D055293:Receptors, Urokinase Plasminogen Activator / Q000378:metabolism*
chemical_list: D055293:Receptors, Urokinase Plasminogen Activator; D066246:ErbB Receptors
keywords: EGFRvIII; LRP1; cell invasion; cell migration; epidermal growth factor receptor (EGFR); glioblastoma; paracrine interaction; paracrine signaling; tumor microenvironment; urokinase receptor
references.citation: Oncogenesis. 2013 Jun 24;2:e53
references.pmid: 23797476
references.citation: Cancer Discov. 2014 Aug;4(8):956-71
references.pmid: 24893890
references.citation: J Histochem Cytochem. 2001 Feb;49(2):237-46
references.pmid: 11156692
references.citation: Blood. 2005 Mar 1;105(5):2198-205
references.pmid: 15494432
references.citation: Nature. 1985 Jan 10-18;313(5998):144-7
references.pmid: 2981413
references.citation: J Biol Chem. 2005 Jul 1;280(26):24792-803
references.pmid: 15863511
references.citation: Cancer Res. 2003 Oct 15;63(20):6962-70
references.pmid: 14583498
references.citation: J Proteome Res. 2011 Mar 4;10(3):1343-52
references.pmid: 21214269
references.citation: J Infect. 2011 Nov;63(5):344-50
references.pmid: 21839112
references.citation: J Biol Chem. 1995 Apr 28;270(17):9709-16
references.pmid: 7730348
references.citation: Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12550-5
references.pmid: 25114226
references.citation: EMBO J. 1996 Apr 1;15(7):1572-82
references.pmid: 8612581
references.citation: Mol Biol Cell. 2006 Jan;17(1):367-78
references.pmid: 16267271
references.citation: Blood. 2000 Dec 15;96(13):4091-5
references.pmid: 11110678
references.citation: J Neurooncol. 2013 Oct;115(1):27-35
references.pmid: 23877363
references.citation: Front Biosci (Landmark Ed). 2009;14:2494-503
references.pmid: 19273214
references.citation: Cancer Res. 1998 Oct 15;58(20):4694-700
references.pmid: 9788624
references.citation: Liver Int. 2012 Mar;32(3):500-9
references.pmid: 22098627
references.citation: Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31
references.pmid: 8052651
references.citation: Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36
references.pmid: 20027185
references.citation: Cancer Res. 2015 Jan 15;75(2):394-404
references.pmid: 25432173
references.citation: Cell. 2013 Oct 10;155(2):462-77
references.pmid: 24120142
references.citation: Oncogene. 2007 Apr 19;26(18):2585-94
references.pmid: 17043637
references.citation: EMBO J. 1997 Dec 15;16(24):7279-86
references.pmid: 9405357
references.citation: Thromb Haemost. 1999 Aug;82(2):259-70
references.pmid: 10605712
references.citation: Circ Res. 1996 Mar;78(3):405-14
references.pmid: 8593699
references.citation: Cancer Res. 2011 Jun 15;71(12):4055-60
references.pmid: 21628493
references.citation: Br J Haematol. 2003 Mar;120(6):953-9
references.pmid: 12648064
references.citation: Acta Oncol. 2010 Aug;49(6):805-11
references.pmid: 20524776
references.citation: J Biol Chem. 1997 Jan 31;272(5):2927-35
references.pmid: 9006938
references.citation: J Biol Chem. 2005 Apr 29;280(17):17449-57
references.pmid: 15728176
references.citation: Cancer Res. 1984 Feb;44(2):753-60
references.pmid: 6318976
references.citation: J Biol Chem. 2001 Feb 9;276(6):3983-90
references.pmid: 11053440
references.citation: Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64
references.pmid: 11818541
references.citation: Stroke. 2012 Dec;43(12):3305-12
references.pmid: 23150653
references.citation: J Biol Chem. 2003 Nov 21;278(47):46692-8
references.pmid: 12963722
references.citation: J Clin Lab Anal. 2012 Jan;26(1):16-21
references.pmid: 24833530
references.citation: N Engl J Med. 2005 Aug 25;353(8):811-22
references.pmid: 16120861
references.citation: Clin Exp Rheumatol. 2011 Sep-Oct;29(5):811-5
references.pmid: 22011479
references.citation: Br J Cancer. 1999 Sep;81(2):203-11
references.pmid: 10496343
references.citation: J Biol Chem. 2002 Dec 6;277(49):46932-9
references.pmid: 12297505
references.citation: Nat Chem Biol. 2009 Feb;5(2):108-17
references.pmid: 19136975
references.citation: FEBS Lett. 2000 Jun 9;475(1):52-6
references.pmid: 10854857
references.citation: Clin Cancer Res. 2002 May;8(5):1132-41
references.pmid: 12006529
references.citation: Nat Med. 2011 Aug;17(8):952-60
references.pmid: 21804539
references.citation: Prostate. 2011 Jun 1;71(8):899-907
references.pmid: 21456072
references.citation: Genes Dev. 2010 Aug 15;24(16):1731-45
references.pmid: 20713517
references.citation: Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2616-21
references.pmid: 20133782
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):609-18
references.pmid: 21239684
references.citation: J Clin Oncol. 2007 Feb 1;25(4):349-55
references.pmid: 17264329
references.citation: Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43
references.pmid: 12461559
references.citation: Am J Respir Cell Mol Biol. 1996 Jul;15(1):78-87
references.pmid: 8679225
references.citation: Am J Clin Pathol. 1994 Dec;102(6):835-41
references.pmid: 7801901
references.citation: Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15984-9
references.pmid: 21896743
references.citation: Cancer Cell. 2002 Jun;1(5):445-57
references.pmid: 12124174
references.citation: FEBS Lett. 1993 Jul 12;326(1-3):69-74
references.pmid: 8392005
references.citation: Oncogene. 2015 Jul 30;34(31):4078-88
references.pmid: 25347738
references.citation: J Cell Physiol. 1999 Aug;180(2):225-35
references.pmid: 10395292
references.citation: Oncogene. 1994 Aug;9(8):2313-20
references.pmid: 8036013
references.citation: Science. 1996 Sep 13;273(5281):1551-5
references.pmid: 8703217
references.citation: J Biol Chem. 2014 Jan 10;289(2):600-16
references.pmid: 24257753
references.citation: Curr Pharm Des. 2011;17(19):1962-9
references.pmid: 21711236
references.citation: Clin Cancer Res. 2008 Sep 15;14(18):5785-93
references.pmid: 18794088